图书馆订阅: Guest
肿瘤形成评论综述™

每年出版 4 

ISSN 打印: 0893-9675

ISSN 在线: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

In Memoriam: Remembering Natale D'Alessandro's Friendship, Collaborations, and Career Research Mechanisms on Drug Resistance in Cancer

卷 26, 册 2, 2021, pp. 1-9
DOI: 10.1615/CritRevOncog.2020036191
Get accessGet access
参考文献
  1. Bonavida B, editor. Genetic and immunochemotherapeutic approaches in cancer treatment. Proceedings of the 43rd Course of the International School of Pharmacology; 1996 May 21-6; Erice, Italy. Athens, Greece: National Hellenic Research Foundation; 1996.

  2. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer. 1999;85(1):134-44.

  3. D'Alessandro N, Gebbia N, Crescimanno M, Flandina C, Leto G, Tumminello FM, Messina L. Effects of amsacrine (m-AMSA), a new aminoacridine antitumor drug, on the rabbit heart. Cancer Treat Rep. 1983;67(5):467-74.

  4. D'Alessandro N, Candiloro V, Crescimanno M, Flandina C, Dusonchet L, Crosta L, Rausa L. Effects of multiple doxorubicin doses on mouse cardiac and hepatic catalase. Pharmacol Res Commun. 1984;16(2):145-51.

  5. D'Alessandro N, Nicotra C, Crescimanno M, Rausa L. Effects of doxorubicin on mouse heart catalase. Drugs Exp Clin Res. 1987;13(10):601-6.

  6. Crescimanno M, Flandina C, Rausa L, Sanguedolce R, D'Alessandro N. Morphological changes and catalase activity in the hearts of CD 1 mice following acute starvation or single doses of doxorubicin, epirubicin or mitoxantrone. Chemioterapia. 1988;7(1):53-9.

  7. Flandina C, Sanguedolce R, Rausa L, D'Alessandro N. Ameliorative effects of ICRF-187 (+)-1,2-bis(3,5-dioxo-piperazinyl-1-yl)propane on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res Com mun Chem Pathol Pharmacol. 1990;70(3):259-72.

  8. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells: Analysis of their possible relationship to changes in NF-KB activation levels and in IAP gene expression. Cancer Lett. 2005;224(1):53-65.

  9. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620-37.

  10. Poma P, Notarbartolo M, Labbozzetta M, Maurici A, Carina V, Alaimo A, Rizzi M, Simoni D, D'Alessandro N. The antitumor activities of curcumin and of its isoxazole analog are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: Analysis of the possible molecular basis. Int J Mol Med. 2007;20(3):329-35.

  11. Simoni D, Rizzi M, Rondanin R, Baruchello R, Marchetti P, Invidiata FP, Labbozzetta M, Poma P, Carina V, Notarbartolo M, Alaimo A, D'Alessandro N. Antitumor effects of curcumin and structurally beta-diketone modified analogs on multidrug resistant cancer cells. Bioorg Med Chem Lett. 2008;18(2):845-9.

  12. Labbozzetta M, Notarbartolo M, Poma P, Maurici A, Inguglia L, Marchetti P, Rizzi M, Baruchello R, Simoni D, D'Alessandro N. Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Ann N Y Acad Sci. 2009;1155:278-83.

  13. Labbozzetta M, Baruchello R, Marchetti P, Gueli MC, Poma P, Notarbartolo M, Simoni D, D'Alessandro N. Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin: Implications for their antitumor and chemosensitizing activities. Chem Biol Interact. 2009;181(1):29-36.

  14. Cervello M, Notarbartolo M, Landino M, Cusimano A, Virruso L, Montalto G, D'Alessandro N. Downregulation of wild-type beta-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: A possible role in the growth-regulatory effects of the cytokine? Eur J Cancer. 2001;37(4):512-19.

  15. Nishioka C, Ikezoe T, Jing Y, Umezawa K, Yokoyama A. DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. Immunology. 2008;124(2):198-205.

  16. Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: Analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol. 2006;28(4):923-30.

  17. Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, Montalto G, D'Alessandro N. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci. 2006;1089:268-75.

  18. Crescimanno M, D'Alessandro N, Armata MG, Toulmond S, Tapiero H. Modulation of the antioxidant activities in dox-sensitive and -resistant Friend leukemia cells: Effect of doxorubicin. Anticancer Res. 1991;11(2):901-3.

  19. Crescimanno M, Armata MG, Florena AM, Leonardi V, Rausa L, D'Alessandro N. Antioxidant defenses in a B16 melanoma line resistant to doxorubicin: An in vivo study. Anticancer Drugs. 1991;2(5):481-6.

  20. D'Amico C, Crescimanno M, Armata MG, Leonardi V, Palazzoadriano M, D'Alessandro N. Beta-adrenergic influences on doxorubicin-sensitive or -resistant P388 leu-kemia cells. Anticancer Res. 1992;12(6B):2253-6.

  21. Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide. 2009;20(1):39-52.

  22. Bonavida B, Garban H. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics. Redox Biol. 2015;6:486-94.

  23. Borsellino N, Crescimanno M, Flandina C, Leonardi V, Rausa L, D'Alessandro N. Antiproliferative and chemo-modulatory effects of interferon-gamma on doxorubicin-sensitive and -resistant tumor cell lines. Anticancer Drugs. 1993;4(2):265-72.

  24. Borsellino N, Crescimanno M, Leonardi V, D'Alessandro N. Effects of 8-chloro-cyclic adenosine monophosphate on the growth and sensitivity to doxorubicin of multidrug-resistant tumour cell lines. Pharmacol Res. 1994;30(1):81-90.

  25. Crescimanno M, Borsellino N, Leonardi V, Flandina C, Flugy A, Rausa L, D'Alessandro N. Effect of buthionine sulfoximine on the sensitivity to doxorubicin of parent and MDR tumor cell lines. J Chemother. 1994;6(5):343-8.

  26. Borsellino N, Crescimanno M, Flandina C, Flugy A, D'Alessandro N. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: Evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects. Anticancer Res. 1994;14(6B):2643-8.

  27. D'Alessandro N, Borsellino N. In vivo effects of tumor necrosis factor-alpha or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma. Anticancer Drugs. 1996;7(3):281-7.

  28. Carollo M, Parente L, D'Alessandro N. Dexamethasone-induced cytotoxic activity and drug resistance effects in androgen-independent prostate tumor PC-3 cells are mediated by lipocortin 1. Oncol Res. 1998;10(5):245-54.

  29. Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papoff G, Ruberti G, Rausa L. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis. Cell Death Differ. 1998 Sep;5(9):735-42.

  30. Callari D, Sinatra F, Paravizzini G, Libra M, Emmanuele G, Fiore B, Pezzino MF, Rasa D, Mazzarino MC, D'Alessandro N, Travali S. All trans retinoic acid sensitizes colon cancer cells to hyperthermia cytotoxic effects. Int J Oncol. 2003;23(1):181-8.

  31. Meli M, Tolomeo M, D'Alessandro N, Grimaudo S, Notarbartolo M, Papoff G, Ruberti G, Rausa L, Dusonchet L. Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis. Anticancer Res. 2004;24(2B):851-7.

  32. Cusimano A, Fodera D, D'Alessandro N, Lampiasi N, Azzolina A, Montalto G, Cervello M. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther. 2007;6(9):1461-8.

  33. Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol. 2009;76(2):290-300.

  34. Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D'Alessandro N, Montalto G, Cervello M. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle. 2010;9(7):1399-410.

  35. Bonavida B. RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-KB/ Snail/YY1/RKIP resistance-driver loop. Crit Rev Oncog. 2014;19(6):431-45.

  36. Notarbartolo M, Giannitrapani L, Vivona N, Poma P, Labbozzetta M, Florena AM, Porcasi R, Muggeo VM, Sandonato L, Cervello M, Montalto G, D'Alessandro N. Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma. OMICS. 2011;15(5):267-72.

  37. Poma P, Labbozzetta M, Vivona N, Porcasi R, D'Alessandro N, Notarbartolo M. Analysis of possible mechanisms accounting for Raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma. OMICS. 2012;16(11):579-88.

  38. Cusimano A, Puleio R, D'Alessandro N, Loria GR, Mc-Cubrey JA, Montalto G, Cervello M. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 2015;6(3): 1707-22.

  39. Poma P, Labbozzetta M, D'Alessandro N, Notarbartolo M. NF-KB is a potential molecular drug target in triple-negative breast cancers. OMICS. 2017;21(4):225-31.

  40. Notarbartolo M, Labbozzetta M, Pojero F, D'Alessandro N, Poma P. Potential therapeutic applications of MDA-9/syntenin-NF-KB-RKIP loop in human liver carcinoma. Curr Mol Med. 2018;18(9):630-9.

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain